# **PROGRAMME**

# Sixth Extended Reitox week

27 November – 1 December 2017

Lisbon

### Coordination meeting with EMCDDA-IPA6 project beneficiary countries

(Bosnia and Herzegovina, former Yugoslav Republic of Macedonia, Kosovo\*, Montenegro and Serbia)

The objective of this informal meeting is to discuss the implementation of the new EMCDDA—IPA6 project. Participants are welcomed to share recent developments in their countries in the field of drugs.

Monday 27 November 2017		
EMCDDA building, Praça Europa 1, Cais do Sodré, CDS 106 (Roger Lewis room)		
14.00	Welcome and opening remarks	
	Chair: Cécile Martel, EMCDDA	
	Presentation of the EMCDDA-IPA6 project and planned activities for 2017–18	
	State of the art and expectations at national level	
	Open discussion	
15.30	End of the meeting	

<sup>\*</sup> This designation is without prejudice to positions on status, and is in line with UNSCR 1244 and the ICJ Opinion on the Kosovo declaration of independence. This applies to all mentions of Kosovo in this document.

## Migration and drugs: challenges and opportunities for monitoring

Tuesday 28 November 2017		
Conference Centr	e, Praça Europa 4, Cais do Sodré	
09.45	<ul> <li>Plenary session I: Introduction and setting the see</li> <li>Chair: Gonçalo Felgueiras, EMCDDA, co-chair: Cée</li> <li>Welcome address and objectives of the meet</li> <li>Migration and drugs: security and surveillance Health Institute, Liverpool John Moores Unive</li> <li>Migration and public health potential threats Migration, Health and Development, Geneva</li> <li>Juergen Serve, Frontex</li> </ul>	cile Martel, EMCDDA ring e challenges — Prof. Marie-Claire Van Hout, Public ersity
11.00	Coffee break/Photo	
11.30	Parallel sessions: Migration and drugs – National	situation and perspectives
	<ul> <li>Migration and drugs – threats and vulnerabilities</li> <li>What do we know about the use of drugs among migrants, risk and protective factors, and the potential for related harm? What do we need to know and how can this be obtained?</li> <li>Chair: Viktor Mravcik, Head of Czech Focal Point Discussant: Marie-Claire Van Hout</li> <li>Unaccompanied minor-aged refugees and substance use' — Marion Weigl, Head of Austrian NFP</li> <li>Mental health issues and drugs concerning the refugee population in Greece — Manina Terzidou, Head of Greek NFP</li> <li>'Drug Crime and Migration: Overview of Internal Security Environment: Case Study Greece' — Konstantina Stergiatou, Police Major, Narcotics Subdivision, General Investigation Unit, Hellenic Police</li> <li>'The migration in Ukraine (trends, challenges) and prevention of diversion of drugs to the EU countries' — Anna Onishchenko, International Relations Department of the UMMCDA, Ukraine</li> </ul>	Migration and drugs – Responses at national level  What do we know about the availability of responses in the countries of origin and in the EU Member States? What do we need to know and how?  Chair: Carmen Andrés, Spanish NFP  Discussant: Liljana Ignatjova (former Yugoslav Republic of Macedonia)  Research 'Studying ethnicity, problem substance use and treatment: From epidemiology to social change' — Lies Gremeaux, Head of Belgium NFP  Changing patterns of drug and alcohol use among 1st and 2nd generation adolescent immigrants to Israel, from Ethiopia and the Former Soviet Union — Prof. Yossi Harel-Fisch, Chief Scientist, IADA; Director of the International research Program on Adolescent Well-Being and Health, Bar Illan University, Israel  'Guidance-Interregional counselling centre for refugees who use addictive substances in Berlin—a report on challenges,
		opportunities and difficulties' — Michael Frommhold, Notdienst Berlin, Germany
13.00	Lunch break	
14.15	Plenary session II – Feedback from parallel sessio     Feedbacks from rapporteurs	ons
15.00	Plenary session III – Overall picture and opportunities for monitoring at EU level  Responses addressing the needs of migrants, EDRR 2017 — Nicola Singleton, EMCDDA, Scientific analyst/writer, Public Health unit	
16.00	End of the meeting	
19.00	Social event	

# 57th Reitox network meeting

Wednesday 29 November 2017		
Conference Centre, Praça Europa 4, Cais do Sodré		
09.00	Pre-Reitox meeting (CdS 012)	
13.00	Lunch break	
14.00	Plenary session I: Introduction and follow-up of previous meetings  Chair: Gonçalo Felgueiras e Sousa  Adoption of the agenda and follow-up of decisions taken during the previous HNFP meeting (May 2017)  Debriefing from the pre-Reitox meeting by the Reitox spokesperson	
14.15	Plenary session II: Update on key recent and future policy and institutional developments  Chair: Gonçalo Felgueiras e Sousa  EMCDDA  Member States/Focal points  EU institutions  EU agencies, international organisations and third countries	
15.00	Coffee break	
15.30	Plenary session III: Reitox network development network  Chair: Lies Gremeaux  Presentation of the draft (by the Joint Working Group) and Feedback from the technical meeting of 12 October (from NFP)  Final discussion, adoption and next steps	
17.30	End of the day	

Thursday 30 November 2017		
09.00	Plenary session IV: National reporting package — Feedback on the revised workbooks and preparation of the 2018 reporting  Chair: Paul Griffiths  1st feedback on the 2017 submission (state of the situation)  Feedback from the technical meeting of 12 October (from NFP) on the revised workbooks (SQ integration) and other revised ST  Follow-up of the Rapid Information Requests 2017  Adoption of the 2018 national reporting guidelines  Audit on EMCDDA data collection: state of the situation	
10.15	Plenary session V: Country Drug Report (CDR): Preparation of the 2018 CDR  Chair: Rosemary Martin de Sousa  NFPs feedback on national experiences post launch 2017  Planning and production process 2018	
11.00	Coffee break	

11.30	<ul> <li>Plenary session VI: Updates on activities — Drug markets, crime and supply reduction</li> <li>Chair: Roumen Sedefov</li> <li>Launch of EMCDDA-Europol publication: Drugs and darknet markets: perspectives for enforcement, research and policy</li> <li>Update from the Reference Group on supply indicators</li> <li>Update on progress on improvement of supply indicators</li> <li>New supply monitoring concepts and techniques</li> </ul>
12.30	Lunch break
13.30	Plenary session VII: Updates on activities — Health related issues  Chair: Jane Mounteney  Highlights from KI meetings  Health and social responses to drug problems: a European guide  Exchange project — state of the art  Update on drug policy evaluation support and 7 step Guide
14.30	Coffee break
15.00	Parallel sessions  Chairs: tbd  NFPs and EU research projects: feedback from current projects  A selected topic from the EMCDDA Health and social responses to drugs problems – A European guide
16.30	Bilateral meetings
17.00	End of the day

Firday 1 December 2017		
Conference Centre, Praça Europa, Cais do Sodré		
09.00	Plenary session VIII: RTX network: Accreditation  Chair: Cécile Martel  Accreditation: feedback from the piloting countries + Feedback from the technical meeting of 12 October (from NFP)  Presentation of the revised self-assessment questionnaire	
10.15	Plenary session IX: Cross-cooperation projects  Chair: Ruxanda Iliescu  EMCDDA International Cooperation Framework  Reitox Academies (feedback on RTX academies 2017 and upcoming RTX academies 2018)  EU research projects: update and feedback from the parallel session  Calendar of Reitox meetings for 2018: HNFP, Technical meetings and Reitox Academies	
11.45	Plenary session X: Conclusions and way forward Chair: Gonçalo Felgueiras e Sousa	
12.00	End of the meeting	